Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2641 to 2655 of 9102 results

  1. Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]

    Awaiting development Reference number: GID-TA11403 Expected publication date:  27 May 2027

    Technology appraisal guidance
    Awaiting development

  2. Miniature lens system implantation for advanced age-related macular degeneration

    In development Reference number: GID-HTG10468 Expected publication date: TBC

    HealthTech guidance
    In development

  3. Frailty: identification and assessment in adults

    Awaiting development Reference number: GID-NG10555 Expected publication date: TBC

    NICE guideline
    Awaiting development

  4. Polyendocrine Metabolic Ovarian Syndrome (PMOS): draft guidance

    We are listening to your views on this NICE guideline. Comments close 11 August 2026.

    NICE guideline
    In consultation

  5. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies (deferred appraisal of D5) [GID-TA12518]

    Awaiting development Reference number: GID-TA12518 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [D5]

    Deferred Reference number: GID-TA10905

    Technology appraisal guidance
    Deferred

  7. Polyendocrine Metabolic Ovarian Syndrome (PMOS)

    In development Reference number: GID-NG10436 Expected publication date:  09 December 2026

    NICE guideline
    In development

  8. Familial Breast Cancer: initial assessment and genetic testing (update)

    In development Reference number: GID-NG10438 Expected publication date:  22 April 2027

    NICE guideline
    In development

  9. Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 1 July 2026.

    Technology appraisal guidance
    In consultation

  10. Ruxolitinib cream for treating moderate atopic dermatitis after topical corticosteroids and calcineurin inhibitors ID6602

    In development Reference number: GID-TA11809 Expected publication date:  03 June 2027

    Technology appraisal guidance
    In development

  11. Surgical mesh for treatment of non-primary ventral hernias

    In development Reference number: GID-HTG10165 Expected publication date:  24 June 2027

    HealthTech guidance
    In development

  12. Excimer laser trabeculotomy for open angle glaucoma

    In development Reference number: GID-HTG10469 Expected publication date: TBC

    HealthTech guidance
    In development

  13. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]

    Awaiting development Reference number: GID-TA11639 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713

    In development Reference number: GID-TA11952 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Excimer laser trabeculotomy for open angle glaucoma

    Awaiting development Reference number: GID-HTG10469 Expected publication date: TBC

    HealthTech guidance
    Awaiting development